CA-WETA-DIGITAL/AUTODESK
17.6.2021 15:02:07 CEST | Business Wire | Press release
Weta Digital, one of the world’s premiere visual effects studios, has partnered with global media and entertainment software provider, Autodesk, Inc. (NASDAQ: ADSK ), to launch WetaM - a ground breaking product offering that provides tools designed and developed by Weta Digital, fully embedded in Autodesk Maya. Weta Digital has won 13 Academy Sci-tech Awards for its tools that helped artists produce some of the most successful film and TV series in the world, including “The Lord of the Rings,” “Avatar,” “Game of Thrones,” and “Planet of the Apes,” to name a few. Weta intends to rollout WetaM as a private beta in Q4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005301/en/
WetaM productizes Weta’s unique set of proprietary VFX tools for artists built on Maya’s open API, and will be commercialized by Weta Digital as a subscription cloud service. For the first time, artists from around the world will have access to one complete—from stage to screen—cloud based pipeline. The launch of WetaM marks the first product launch under a newly formed Software-as-a-Service (SaaS) division within Weta Digital. This new business arm is an integral part of Weta’s expansion strategy to offer professional and prosumer tools to artists across the global entertainment industry.
“WetaM is the first step in the democratization of VFX and animation production. Weta Digital brings together the most creative minds in the world and has been a pioneering innovator in the visual effects and entertainment industry for decades,” said Prem Akkaraju, CEO of Weta Digital. “WetaM is a transformational move that will raise the bar for global creative production, redefining the industry in the process. At its core, this partnership with Autodesk will extend the reach of the Weta magic, making it more accessible for artists in pursuit of creating amazing characters and worlds across film and television.”
“We are longtime fans of Weta’s remarkable visual effects achievements, and they are constantly breaking new ground building immersive, imaginary worlds and unbelievably real and engaging digital characters,” said Diana Colella, senior vice president, Entertainment & Media Solutions, Autodesk. “The debut of WetaM is a gamechanger as it opens up years of Weta’s dedicated animation and VFX R&D resources to all creatives. It is exciting to be working with Weta to bring their magic to Maya artists, offering them powerful new effects tools and time-saving automation capabilities.”
As a leader in VFX and animation for the last three decades, Weta Digital’s DNA is rooted in technological innovation, unmatched artistic talent and exceptional visual style. Brought to life through the partnership with Autodesk, WetaM shares this DNA and gives artists, everywhere, access to the unique visual design and pipeline efficiency tools that have driven Weta Digital’s Academy® Award-winning success.
ABOUT WETA DIGITAL
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
ABOUT AUTODESK
Autodesk makes software for people who make things. If you've ever driven a high-performance car, admired a towering skyscraper, used a smartphone, or watched a great film, chances are you've experienced what millions of Autodesk customers are doing with our software. Autodesk gives you the power to make anything. For more information, visit www.autodesk.com or follow @autodesk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005301/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom